Leveraging AI and Machine Learning for Smarter Clinical Trial Design

How does a late-stage clinical trial fail when the preceding trials showed such promise? The likely reason is that the patients in the earlier trials were not representative of the larger population. Clinical trial participation is shaped by stringent enrollment criteria, and access to trial centres, as well as socioeconomic and demographic factors, are key determinants. To improve clinical trial representativeness, the medical community must broaden community access, focus on diversity and inclusion in enrollment, and factor in adaptive trial designs and precision patient-trial matching.